RE:Very good data There's really only one data point that's novel, the fact that combo'ing th1902 with CPIs leads to enhanced activity in mice. The rest seems like more of the same (great) story we've been getting from preclinical all along.
The only data that really matters is the 20-30 (or whatever) patients enrolled in 1b that they have and aren't sharing. Certainly bad, not great, maybe as bad as it could be, who knows.
Trogarzon wrote: This is good data. It now depends on their capacity to sell it to the market.